



Market snapshot



Equities - India	Close	Chg .%	CYTD.%
Sensex	72,990	-0.1	-6.6
Nifty-50	22,083	-0.2	-6.6
Nifty-M 100	48,008	0.0	-16.1
Equities-Global	Close	Chg .%	CYTD.%
S&P 500	5,778	-1.2	-1.8
Nasdaq	18,285	-0.4	-5.3
FTSE 100	8,759	-1.3	7.2
DAX	22,327	-3.5	12.1
Hang Seng	8,367	-0.6	14.8
Nikkei 225	37,331	-1.2	-6.4
Commodities	Close	Chg .%	CYTD.%
Brent (US\$/Bbl)	72	-2.8	-3.2
Gold (\$/OZ)	2,918	0.9	11.2
Cu (US\$/MT)	9,328	-0.7	7.8
Almn (US\$/MT)	2,627	0.1	3.9
Currency	Close	Chg .%	CYTD.%
USD/INR	87.3	-0.1	1.9
USD/EUR	1.1	1.3	2.6
USD/JPY	149.8	0.2	-4.7
YIELD (%)	Close	1MChg	CYTD chg
10 Yrs G-Sec	6.7	0.01	0.0
10 Yrs AAA Corp	7.5	0.03	0.2
Flows (USD b)	4-Mar	MTD	CYTD
FIIs	-0.4	-0.92	-14.3
DIIs	0.56	2.12	19.0
Volumes (INRb)	4-Mar	MTD*	YTD*
Cash	921	966	993
F&O	98,383	1,09,551	1,84,988

الم

Today's top research idea

Bharti Airtel: Focus likely to intensify on capital allocation plans

- Driven by tariff repair in the India wireless segment, Bharti's FCF generation improved significantly over the past few years (9MFY25: INR292b). Bharti's main priority for cash deployment so far has been prepaying high-cost debt.
- With a complete flow-through of tariff hikes and a moderation in capex intensity, Bharti is likely to generate significant FCF (~INR1.3t over FY25-27E).
- With high-cost debt largely repaid and leverage under control, we believe capital allocation remains the key monitorable and would likely be the biggest driver for Bharti's stock price performance over the medium term.
- Our FY25-27 estimates are broadly unchanged as we build in FY24-27 CAGR of ~15%/19% in Bharti's consolidated revenue/EBITDA. We reiterate our BUY rating on Bharti with a revised TP of INR1,985 (earlier INR1,990).



Research covered

Cos/Sector	Key Highlights
Bharti Airtel	Focus likely to intensify on capital allocation plans
DCB Bank	Growth outlook steady; RoA likely to improve to 1%
Utilities	India set to embrace nuclear energy - II

Note: Flows, MTD includes provisional numbers.

^{*}Average



Chart of the Day: Bharti Airtel (Focus likely to intensify on capital allocation plans)

Bharti's FCF after spectrum payments, leases and interest to improve sharply to ~INR500b by FY27, on our estimates

Bharti Airtel FCF workings	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Operating Cashflow before WC changes	474	586	722	794	1,004	1,158	1,322
Working Capital changes	30	-14	-31	24	59	61	60
Taxes	-22	-22	-38	-29	-72	-124	-162
CFO before leases and interest	482	550	653	789	990	1,095	1,220
Leases	-64	-76	-76	-79	-73	-69	-66
Interest paid	-71	-132	-67	-140	-200	-185	-165
CFO post interest and leases	347	342	510	570	718	840	989
Capex	-336	-435	-388	-521	-507	-407	-421
FCF post interest and leases	11	-93	122	49	211	433	568
Spectrum prepayments		243	62	163	200		
FCF before spectrum prepayments		151	185	213	411	433	568
Regulatory payouts – principal component			21			25	67
FCF post spectrum payments, leases and interest	11	151	164	213	411	408	502





In the news today



Kindly click on textbox for the detailed news link

1

NSE changes expiry of all F&O contracts from Thursday to Monday effective April 4

The National Stock Exchange (NSE) on March 4 said all Nifty index weekly futures and options (F&O) contracts will expire on Monday instead of Thursday with effect from April 4.

2

Adani Wilmar to acquire GD Foods, owner of prominent FMCG brand 'Tops'

Adani Wilmar, the FMCG major known for its 'Fortune' brand, has signed a definitive agreement to acquire GD Foods, a leading player in the sauces and pickles category and the owner of 'Tops' brand.

3

Ola Electric gets IFCI notice for missing PLI-ACC scheme milestones

Ola Electric Mobility whollyowned subsidiary has received a letter from IFCI for missing out on targets specified under the Production Linked Incentive Advanced Chemistry Cell scheme (PLI ACC). 4

Zydus Life to develop world's first dual vaccine for typhoid and Shigella

Zydus Lifesciences is set to develop the world's first combination vaccine for typhoid and shigellosis. The initiative, backed by the Bill & Melinda Gates Foundation, aims to protect infants and children in endemic regions.

5

Dr Reddy's sells 14-drug portfolio to Senores Pharma for US market expansion

Dr Reddy's Laboratories Ltd has entered into an agreement with Ahmedabad-based Senores Pharmaceuticals Ltd to sell a portfolio of 14 Abbreviated New Drug Applications (ANDAs) for an undisclosed amount.

6

Coca-Cola to sell bottling plant in North Gujarat to Kandhari Global Beverages for Rs 2,000 crore

Though the company has not shared financial details, industry insiders have pegged the deal to be around Rs 2,000 crore, where Coca-Cola will transfer business from HCCBL, its bottling arm in India, to its bottling partner Kandhari Global Beverages.

7

Biocon gets FDA nod for cancer drugs lenalidomide and dasatinib

Biocon Ltd wholly-owned subsidiary, Biocon Pharma Ltd, has received final approvals from the US Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDAs).



Bharti Airtel

 BSE SENSEX
 S&P CNX

 72,990
 22,083



Bloomberg	BHARTI IN
Equity Shares (m)	6088
M.Cap.(INRb)/(USDb)	9419 / 107.9
52-Week Range (INR)	1779 / 1132
1, 6, 12 Rel. Per (%)	2/13/40
12M Avg Val (INR M)	10164

Financials & Valuations (INR b)


Y/E MARCH	FY25E	FY26E	FY27E
Net Sales	1,725	2,047	2,309
EBITDA	929	1,158	1,322
PAT	209	273	378
EPS (INR)	36.4	45.1	62.5
GR. (%)	85	24	39
BV/Sh (INR)	182	242	283
Ratios			
ROE (%)	22.8	23.0	25.8
RoCE (%)	14.1	14.8	16.9
Valuations			
P/E (X)	43	35	25
P/BV (X)	8.7	6.5	5.6
EV/EBITDA (X)	11.6	9.3	7.8
Div Yield (%)	1.0	1.6	2.5

Shareholding pattern (%)

As On	Dec-24	Sep-24	Dec-23
Promoter	53.1	53.1	54.6
DII	19.6	18.8	19.7
FII	24.3	25.2	22.7
Others	2.9	2.9	3.0

FII Includes depository receipts

Stock's performance (one-year)



CMP: INR1,580 TP: INR1,985 (+25%) Buy

Focus likely to intensify on capital allocation plans

- Driven by tariff repair in the India wireless segment, Bharti's FCF generation improved significantly over the past few years (9MFY25: INR292b). Bharti's main priority for cash deployment so far has been prepaying high-cost debt.
- With a complete flow-through of tariff hikes and a moderation in capex intensity, Bharti is likely to generate significant FCF (~INR1.3t over FY25-27E).
- With high-cost debt largely repaid and leverage under control, we believe capital allocation remains the key monitorable and would likely be the biggest driver for Bharti's stock price performance over the medium term.
- Our FY25-27 estimates are broadly unchanged as we build in FY24-27 CAGR of ~15%/19% in Bharti's consolidated revenue/EBITDA. We reiterate our BUY rating on Bharti with a revised TP of INR1,985 (earlier INR1,990).

Annual FCF generation likely to top INR500b by FY27

- Bharti's FCF generation (after lease and interest) improved to INR292b in 9MFY25 (from INR213b in FY24), driven by tariff repair-led improvement in operating cashflows and a reduction in capex with the completion of the first phase of 5G rollouts.
- The improved FCF generation has been used to prepay the high-cost spectrum debt (9.3-10% interest rate).
- Bharti has prepaid ~INR200b spectrum debt in 9MFY25 and ~INR670b since FY22, clearing all the spectrum liabilities pertaining to 2012, 2014, 2015 and 2016 spectrum auctions.
- With a full flow-through of the Jul'24 tariff hike, a likely additional tariff hike of ~15%, a moderation in capex, and Indus consolidation, we expect Bharti's FCF (after interest and leases, but before spectrum repayments) to improve to INR570b by FY27 and ~INR500b after regulatory dues payout.

High-cost debt largely paid up; leverage in comfortable zone

- Bharti's ~INR944b dues to the GoI mainly pertains to AGR dues (under moratorium until Mar'26 at 8% interest rate) and 2022 spectrum (at ~7.2% interest rate, paid till Aug'26 except for Hexacom circles).
- Given the benign interest rate for the remaining GoI dues (~7.2-8.65%) and telcos still hopeful of some relief on AGR dues, we do not expect Bharti to prepay further spectrum or AGR dues.
- Bharti's overall net debt, excluding DPL and lease liabilities, stood at a modest INR392b (vs. annualized EBITDAaL of INR1.04t). Given robust FCF generation, we expect Bharti's non-Gol debt to be largely repaid by FY27.

Capital allocation would be the key monitorable for Bharti

With leverage under control, India wireless capex moderating, and no immediate requirement for additional spectrum on the horizon, the deployment of Bharti's rising FCF is likely to become the most important monitorable for potential stock price performance in the medium term.



 Bharti's management indicated that deleveraging, increasing shareholder returns through higher dividends, and bolt-on acquisitions to boost capabilities in Enterprise business remain the key priorities for capital deployment.

Dividend payout to increase meaningfully to service promoter-level debt

- Bharti Telecom (BTL, a 51:49 JV between Bharti Enterprises and Singtel) has purchased stake worth ~INR381b from Bharti Airtel's promoters and through rights issue over the last few years to raise its stake to 40.5%.
- As the dividend from Bharti is the only source of revenue for BTL, the debt on BTL's balance sheet has increased to ~INR380b, largely due to Bharti's stake purchases. The debt-to-equity ratio for BTL has spiked to 5.4x as of Dec'24.
- As per our estimates, Bharti's FY25 dividend payout would have to increase to at least INR14/share (vs. INR8/share) for BTL to service its interest payments.
- BTL has to either repay or refinance ~INR215b dues over Sep'25 to Feb'26.
- Further, BTL has to contribute ~INR58 toward pending calls on the rights issue and might have to purchase an additional stake from promoters as 1) Singtel looks to equalize its direct stake with Bharti, and 2) promoters are keen to consolidate their holdings in Bharti under BTL.
- Given the need for servicing its existing debt and potentially funding additional stake purchases, we believe that increasing the dividend payout is likely to become the biggest priority for Bharti over the next few years.
- However, Bharti's recent stake increase in Airtel Africa, the Indian promoter's continued stake sales in Bharti, and discussions for a potential merger of Airtel DTH with Tata Play have raised some concerns about capital allocation priorities.

AAF stake purchase driven by potential value-unlocking triggers

- Bharti has recently purchased a ~4.45% stake in Airtel Africa (AAF) for a total consideration of ~INR23.6b.
- While investors would prefer Airtel to pay out higher dividends or invest the cashflows in Indian operations, we do not see the investment made to increase the stake in AAF as a capital misallocation.
- AAF has been delivering robust double-digit constant currency (cc) growth for the past several years, and we remain positive on AAF, given the long runway for data and mobile money growth in Africa.
- Despite robust growth, AAF trades at subdued ~3.8x FY27E EBITDA. We believe a sharp tariff hike in Nigeria and an impending IPO of Mobile Money (Jul'25) could be key near-term value-unlocking triggers for AAF, which would benefit Bharti's shareholders as well.
- Moreover, Bharti will likely be able to recoup the investments in the AAF stake purchase through upcoming inflows from Indus Tower. As such, we do not expect any significant impact on Bharti's FY25 dividends due to the AAF stake purchase.



Airtel DTH – Potential Tata Play merger to boost Airtel's convergence play

- Bharti recently confirmed that the company is in bilateral discussions with the Tata Group to explore a potential transaction to combine Tata Play and Airtel DTH.
- Given structural headwinds, we believe a potential merger between Airtel DTH and Tata Play is unlikely to create any significant value for Airtel's DTH operations on a standalone basis.
- However, the deal would provide Airtel with access to additional ~19m highpaying homes, which the company can tap to offer its converged offerings under Airtel Black.

Valuation and view

- Our FY25-27 estimates are broadly unchanged. We build in FY24-27 CAGR of ~15%/19% in consolidated revenue/EBITDA, driven by more frequent tariff hikes in India wireless business (~12.5% ARPU CAGR), acceleration in Homes broadband services, and robust double-digit growth in Africa.
- We continue to like Bharti's superior execution on the premiumization agenda. With a moderation in capex intensity, Bharti is likely to generate significant FCF (~INR1.3t over FY25-27E), which should lead to significant deleveraging and improvement in shareholder returns.
- We believe capital allocation remains the key monitorable and would likely be the biggest driver for Bharti's stock price performance over the medium term.
- We reiterate BUY on Bharti with our SoTP-based TP of INR1,985. We value India wireless and homes business on DCF (implies ~13x FY27 EV/EBITDA), DTH/Enterprise at 4.5x/10x Mar'27E EBITDA and BHARTI's stake in Indus Towers and Airtel Africa at a 25% discount to our TP/CMP.

Our SoTP-based TP for Bharti is INR1,985/share

	Valuation ba	ase (INR b)	IV	1ultiple (x)	Va	luation
Mar'27 basis	EBITDA	Other	EBITDA	Other	(INR b)	(INR/share)
India business						
India wireless (including Hexacom)	819		13.0	DCF implied	10,645	1,760
Less: Hexacom minority (30% minority)	63		10.9	Implied at CMP	205	34
Homes	49		13.0	DCF implied	635	105
India homes + wireless attributable value					11,075	1,831
DTH	18		4.5		80	13
Enterprise	83		10.0		827	137
Indus Towers attributable value	163	528	6.5	0.75	396	65
Other investments (Nxtra, APB)		148		1	148	25
India business enterprise value	1,060		11.8	Implied	12,526	2,071
India business net debt (including leases)					927	153
Network I2I perps					132	22
India business equity value (a)					11,467	1,896
International business						
Airtel Africa	272		3.3	Implied at CMP	906	157
Airtel Africa net debt					327	57
Airtel Africa attributable value		357		0.75	268	44
Robi Axiata + Dialog SL attributable value		33		0.75	25	4
International business equity value (b)					293	48
Dividends (c)					246	41
Bharti Airtel TP (d) = (a) + (b) + (c)					12,007	1,985



DCB Bank

 BSE SENSEX
 S&P CNX

 72,990
 22,083

CMP: INR102 TP: INR150 (+47%) Buy

DCB BANK

Stock Info

Bloomberg	DCBB IN
Equity Shares (m)	314
M.Cap.(INRb)/(USDb)	32 / 0.4
52-Week Range (INR)	146 / 101
1, 6, 12 Rel. Per (%)	-7/-4/-20
12M Avg Val (INR M)	249

Financials & Valuations (INR b)


The state of the s						
Y/E MARCH	FY24	FY25E	FY26E			
NII	19.3	21.1	25.9			
OP	8.6	10.2	13.3			
NP	5.4	6.0	7.5			
NIM (%)	3.7	3.3	3.4			
EPS (INR)	17.1	19.2	23.9			
EPS Gr. (%)	14.6	12.2	24.5			
BV/Sh. (INR)	157	174	195			
ABV/Sh. (INR)	147	161	182			
Ratios						
RoA (%)	0.9	0.9	0.9			
RoE (%)	11.8	11.9	13.3			
Valuations						
P/E (x)	6.0	5.3	4.3			
P/BV (x)	0.6	0.6	0.5			
P/ABV (X)	0.7	0.6	0.6			

Shareholding pattern (%)

As On	Dec-24	Sep-24	Dec-23
Promoter	14.7	14.7	14.8
DII	27.9	26.7	34.2
FII	10.9	11.1	13.0
Others	46.5	47.6	38.0

FII Includes depository receipts

Stock Performance (1-year)



Growth outlook steady; RoA likely to improve to 1%

Valuations attractive at 0.52x FY26E BV

- DCB Bank (DCBB) has experienced a healthy recovery in loan growth over the past two years after reporting tepid trends over FY20-22. The bank continues to focus on granular retail loans with a retail mix (ex-Agri) at 65% of the overall portfolio.
- DCBB arrested the downward pressure on NIM in 3QFY25, and the bank can maintain a resilient performance despite 25-50bp repo cuts. Aided by a granular liability profile, limited reliance on bulk deposits & improving asset mix, we estimate the bank to retain its NIM at ∼3.4%.
- While opex has been high owing to investments in business, we expect operating leverage to kick in, aiding the move of RoA towards 1%. We believe the C/I ratio has broadly peaked at 64% in FY24 and expect the ratio to moderate to ~59% by FY27E.
- We expect a healthy 22% CAGR in total income over FY25-27 amid limited downside in margins and steady loan growth. We estimate its RoA/RoE to reach 1%/15% by FY27.
- With a likely recovery in loan growth and anticipated improvements in operating leverage, we estimate a 26% earnings CAGR over FY25-27.
- We find the current valuation of 0.52x FY26E ABV attractive for an RoA of ~1% and ~26% earnings CAGR over FY25-27E. We reiterate our BUY rating on the stock with a TP of INR150 (premised on 0.8xSep'26E ABV).

Loan CAGR to be healthy at ~23%, loan book to double in 3-4 years

DCBB is set to maintain a robust growth trajectory with its loan book projected to double over the next 3-4 years (implying 22-23% growth CAGR). The bank reported a 22.7% YoY growth in advances for 3QFY25, reflecting sustained momentum. This growth is fueled by strategic initiatives such as optimizing business from its existing branch network and enhancing digital capabilities to improve customer experience. The bank has focused on expanding granular retail loans and increasing business loan exposure to drive profitable growth. Thus, mortgages now form 53% of the loan book, while co-lending partnerships contribute 11% to advances and have emerged as a significant growth catalyst.

Retail mix healthy; focus remains on improving productivity levels

DCBB continues to strengthen its retail portfolio, with retail loans (ex-Agri) forming ~65% of the loan book, reflecting the bank's emphasis on granular, customer-focused lending. This retail-heavy mix aligns with the bank's strategy to leverage branch-level productivity for sustainable growth. The bank is optimizing its branch network to drive higher business per branch, leveraging digital capabilities and enhancing productivity at existing locations. To drive higher business per branch, the bank has focused on enhancing digital capabilities and improving operational efficiency while maintaining strong cost controls. We thus estimate the C/I ratio to reduce to 61%/59% by FY26E/FY27E from 64% in FY24.



NIM to remain resilient amid repo rate cuts

DCBB's NIM is likely to remain resilient even with a potential ~50bp repo rate cut driven by several strategic levers. The bank looks to cushion its NIM effectively by leveraging SA rate adjustments. DCBB offers higher interest rates in the SA book and thus has the flexibility to review its SA rates, which will help limit the impact of declining interest rates on margins. This is supported by a granular liability profile, limited reliance on bulk deposits, and a favorable asset mix resulting from a deliberate reduction in low-margin corporate loans. Additionally, with deposit re-pricing behind, the bank is better positioned to maintain control of its funding costs while the repricing of asset books that were originated and disbursed a few years ago (fixed-rate in initial years) will support lending yields. We estimate its NIM to sustain at ~3.4-3.5% over FY25-27 (3.3% in 3QFY25) with the CASA mix anticipated to remain stable.

NII growth to track closer to loan growth; operating efficiency to aid RoAs

We estimate NII growth to closely mirror loan growth over FY25-27, propelled by steady advances and resilient margins. Notably, 3QFY25 marked a turnaround for NII growth, signaling a momentum that is expected to continue. During 3Q, the bank reported a 3bp expansion in NIM to reach 3.3%. Further, operational improvements are central to the bank's strategy. It focuses sharply on reducing the C/I ratio, as the bank sees limited requirements to invest in augmenting the existing infrastructure. Improving productivity will be a significant growth driver for DCBB over the coming years. We thus estimate the C/I ratio to improve from 64% in FY24 to 59% by FY27, as we pencil in opex growth at 17% CAGR over FY25-27 (vs. 22% CAGR over FY21-24). With healthy NII growth, a receding C/I ratio amid operating leverage gains, and steady asset quality, we estimate DCBB to report 0.9-1.0% RoA over FY25-27.

Asset quality outlook healthy; credit costs to remain contained at 0.5-0.7%

DCBB's asset quality outlook remains healthy with continued improvements in key metrics underscoring the bank's focus on prudent lending practices and effective risk management. The bank's asset quality resilience is further supported by enhanced collection processes and a restructured book that is steadily declining. DCBB has strengthened its recovery mechanisms, leading to a sharp improvement in collection efficiency, particularly in key segments such as LAP and home loans. A secured portfolio mix and stringent underwriting standards support controlled credit costs, which are projected at 0.5-0.7% over FY25-27. DCBB's proactive risk management, combined with its improved portfolio composition and enhanced collection efficiencies, is expected to drive GNPA reductions. We thus estimate GNPA/NNPA ratios to improve to 2.9%/1.0% by FY26 and credit costs to sustain at 0.6% in FY26.

Valuation attractive at 0.52x FY26E BV; Reiterate BUY

DCBB has seen a healthy recovery in loan growth after witnessing sluggish trends during FY20-22, and we estimate loan growth to remain steady at ~23% CAGR over FY25-27E. The bank's shift in loan mix toward retail loans has helped maintain healthy NIMs. With a healthy retail mix, operating leverage at play, and a resilient NIM outlook, we expect DCB to report sustained traction in the balance sheet and earnings growth. We thus estimate RoA to sustain at 0.9-1% for FY25-27E. We find the current valuations at 0.52x FY26E ABV attractive for a potential RoA of ~1% and ~26% earnings CAGR estimated over FY25-27E. We reiterate our BUY rating with a TP of INR150 (premised on 0.8xSep'26E ABV).



Utilities

Our latest Utilities updates



India set to embrace nuclear energy - II

- We recently published a report on the emerging nuclear landscape in India titled 'India set to embrace nuclear energy' (link), where we discussed: 1) the global nuclear energy landscape (an installed capacity of ~399GW by 2024-end); 2) India's nuclear capacity ambitions of 22GW by 2032 and 100GW by 2047, along with two pathways—conventional and Small Modular Reactors (SMR); and 3) NTPC as the bellwether play for nuclear energy, with projects under planning entailing a total capex of INR1.5t, while private operators such as TPWR and Jindal Nuclear could also take advantage of opportunities in the nuclear space.
- In the second part of this series, we delve into: 1) a comparative analysis of capex and tariffs (INR/kWh) for nuclear vs thermal/solar/wind/hybrid energy sources, evaluating their economic viability; 2) the legal and financial complexities associated with nuclear power, which have been key hurdles to increasing investment in the sector; 3) the challenges related to uranium procurement, geopolitical dependencies, and the risks of time and cost overruns; and 4) the potential for private operators such as Adani Power, Reliance Industries, Vedanta Group, TPWR, and Jindal Nuclear to invest in nuclear power.
- Our key conclusions: 1) capex for conventional nuclear is ~INR180m/MW, with tariffs ranging INR7-8/kWh; 2) nuclear is a long-term solution that addresses the issue of base load supply; 3) we believe private capex in nuclear will take the SMR route, with sizeable commercial investment likely a few years away; 4) clarifying nuclear liability regulations will help advance stalled projects, enhance clean energy capacity, and align India with global advancements in SMRs; 5) uranium supply could emerge as a challenge, as over 50% of global uranium supply is processed by just three countries; 6) the World Nuclear Association (2023) projects a 28% rise in uranium demand by 2030; 7) In India, the Civil Liability for Nuclear Damage Act (CLNDA) places primary liability for nuclear accidents on NPCIL, capping it at INR15b, which we believe could be grossly inadequate in the event of a disaster.

Tariff comparison: Nuclear expensive but addresses base load supply issue

- Electricity costs in India vary significantly depending on the energy source, as shown in this tariff comparison (INR per kilowatt-hour). Solar power leads as the most economical option at INR2.5-2.7/KWh, followed by onshore wind at INR3-3.5/KWh. Hybrid ranges from INR3.2 to 3.6/KWh, while FDRE stands at INR4.5-5/KWh. Thermal power costs INR5-6/KWh.
- Conventional nuclear power is currently the most expensive at INR7-8/KWh. While it is more expensive than plain vanilla solar/wind, it does address the issue of renewables' inability to meet base load supply requirements.

Average tariff by source (India)

Technology	Tariff (INR/kWh)
Solar	2.5-2.7
Onshore Wind	3-3.5
Hybrid	3.2-3.6
Thermal	5-6
Nuclear (Conventional)	7-8
FDRE	4.5-5

Source: MOFSL



Capex comparison: Conventional nuclear power leads at INR180m/MW

In India, the average capital expenditure for power generation varies widely by technology. Solar costs the lowest at INR50m/MW, followed by onshore wind at INR65m/MW, hybrid renewable systems at INR55m/MW, thermal at INR120m/MW, and nuclear the highest at INR180m/MW. These costs are key considerations for any power project development.

Average capex per MW by technology (India)


Technology	INRm/MW
Solar	50
Onshore Wind	65
Hybrid	55
Thermal	120
Nuclear (Conventional)	180

Source: MOFSL

Over 50% of global uranium supply processed by just three countries

- Uranium exploration, like R&D, is a high-risk, high-reward venture. Successful
 exploration identifies mineable deposits, which are then processed into nuclear
 fuel. Recoverable uranium resources are categorized by uranium production
 costs, with the highest cost bracket being <USD60/kgU (7.9mt as of 2021).
- Resources costing up to USD130/kgU are considered the most economically viable and, therefore, the most favorable. Global identified recoverable uranium resources, within the <USD130/kgU cost category, amounted to 6.1mt in 2021.</p>
- However, this supply is heavily concentrated, with **three countries possessing more than 50% of the total**. Despite uranium mining taking place in ~20 countries, in 2022, over half of the world's uranium came from just 10 mines in five countries.

Identified recoverable (<USD130/kgU) Uranium resources- ~6.1mt (as of 2021)



Source: World Nuclear Association, MOFSL







Bajaj Auto: Downbeat consumer sentiment leading to the slowdown in sales; Rakesh Sharma, ED

- Very difficult to extrapolate one month data
- In 125cc+ segment our market share has been 21-23% for 4-5 months
- Despite turbulence in feb, India Should close FY25 with a growth of 6-8%
- There's a downturn in almost all the segments in February
- Certain pockets have been impacted by lack of financing



NHPC: PTC India stake acquisition updates, have capex plans peaked out?; Raj Kumar Chaudhary, CMD

- Will commission Parvati II plant this month
- Parvati II plant will boost revenue by Rs 1900 Crs
- Working on 20 pump storage plant projects
- Planned pump storage investment of Rs 80000 Crs



Suzlon: Power demand, offshore expansion, potential of wind energy & more; JP Chaslani, CEO

- No sign of power demand coming down
- PPA delays are due to multi state approval
- Don't think current issues will halt energy transition in India
- Current wind energy capacity in India stands at 48.5 GW
- India needs to have a 10 GW annual run rate to reach wind capacity targets



Sudarshan Chemical: Revenue has grown by 18% & expect to maintain this momentum; Rajesh Rath, MD

- Aim is to become a world leader with a solid global footprint
- Heubach acquisition gives us exposure to UK & USA
- Total acquisition cost is Rs 2500 Crs of which half will be funded via debt
- Sudarshan chemical revenue has grown by 18% and will maintain this momentum



Allcargo Group: International & domestic business will be separate entities in 3 months; Ravi Jakhar, Chief Strategy Officer

- Confident of double digit growth in the domestic express business
- Contract logistics growing at 40-50%, likely to continue
- Next 3-6 months for international business will remain subdued
- Air volumes will remain around 5% of total surface volumes 95%
- Got shareholders approval for demerger 3 weeks ago



Investment in securities market are subject to market risks. Read all the related documents carefully before investing



Explanation of Investment Rating		
Investment Rating	Expected return (over 12-month)	
BUY	>=15%	
SELL	<-10%	
NEUTRAL	> - 10 % to 15%	
UNDER REVIEW	Rating may undergo a change	
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation	

^{*}In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.moti

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or attention of the public accordance. appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) d)
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.
- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement Companies where there is interest Analyst ownership of the stock No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under

5 March 2025 11



applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motifal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID	
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com	
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com	
Mr. Ajay Menon	022 40548083	am@motilaloswal.com	

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.